Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections

Journal of Chemotherapy

Volumn 24, Issue 3, 2012, Pages 150-154

  Tekçe, Yasemin Tezer ^a   Erbay, Ayşe ^b   Çabadak, Hatice ^a   Şen, Süha ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b BOZOK UNIVERSITY   (Turkey)

Author keywords

Stenotrophomonas maltophilia; Tigecycline; Treatment; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; TIGECYCLINE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOSPITAL INFECTION; HUMAN; MALE; MORTALITY; STATISTICAL SIGNIFICANCE; STENOTROPHOMONAS MALTOPHILIA INFECTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PROGNOSIS; RETROSPECTIVE STUDIES; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL RATE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84866238337     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X12Z.00000000022     Document Type: Article

References (29)

1. Paez JI, Tengan FM, Barone AA, Levin AS, Costa SF. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2008;27:901-6.
2. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis. 2007;26:13-20.
3. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9:312-23
4. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008;62:889-94.
5. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34:1653-6.
6. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect. 2004;37:359-65.
7. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735-7.
8. Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob. 2006;5:23.
9. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009;34:8.e1-9.
10. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis. 2007;26:229-37.
11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128-40.
12. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infection, 1992: a modification of CDC definition of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606-8.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.
14. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2007;59:583-5.
15. Gulmez D, Cakar A, Sener B, Karakaya J, Hasçelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother. 2010;16:322-8.
16. Wood GC, Underwood EL, Croce MA, Swanson JM, Fabian TC. Treatment of recurrent Stenotrophomonas maltophilia ventilator-associated pneumonia with doxycycline and aerosolized colistin. Ann Pharmacother. 2010;44:1665-8.
17. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-99). Clin Infect Dis. 2001;32 Suppl 2: 104-13.
18. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18,569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (19972001). Int J Antimicrob Agents. 2003;22:551-6.
19. Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Picazo JJ. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother. 2002;50:758-9.
20. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents. 2005;25:95-109.
21. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2000;45:115-7.
22. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother. 2008;20:38-42.
23. Passerini de Rossi B, García C, Calenda M, Vay C, Franco M. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Int J Antimicrob Agents. 2009;34:260-4.
24. Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother. 2003;47:816-9.
25. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 2005;52: 187-93.
26. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis. 2005;52:203-8.
27. Belvisi V, Fabietti P, del Borgo C, Marocco R, di Vincenzo E, Soscia F, et al. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. J Chemother. 2009;21:367-8.
28. Blanquer D, de Otero J, Padilla E, Gómez F, Mayol A, Irigaray R, et al. Tigecycline for treatment of nosocomial-acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother. 2008; 20:761-3.
29. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49: 220-9.